- Ginkgo Bioworks specializes in biotechnology with a focus on autonomous lab infrastructure, aiming to revolutionize the drug discovery process and reduce R&D costs, which currently average over $2 billion per asset for large biopharma companies.
- In 2026, Ginkgo launched the Ginkgo Cloud Lab, an autonomous lab platform powered by AI, allowing researchers to conduct experiments remotely and efficiently, while also announcing plans to divest its biosecurity business to focus capital on autonomous labs.
- The company has formed a partnership with ProQR Therapeutics to support AI-enabled drug discovery, leveraging Ginkgo's advanced lab capabilities to accelerate the development of new therapies, with the first AI-discovered drug expected to enter clinical trials in mid-2026.
- Ginkgo's ideal buyers are biopharma companies looking to cut R&D costs and improve efficiency in drug development, as they face increasing pressure from rising trial costs and competition from lower-cost markets like China.
Engineering is the largest function with 496 employees (42.3%). Other teams include Operations (108; 9.2%), Sales and Support (106; 9.0%), Business Management (90; 7.7%), Marketing and Product (86; 7.3%), Finance and Administration (71; 6.1%), Quality (59; 5.0%), Information Technology (45; 3.8%), Human Resources (34; 2.9%), and Other roles (79; 6.7%). The distribution shows a substantial engineering and product footprint supported by operations and go-to-market functions.
The workforce is concentrated in Boston, MA (452; 38.5%), with additional clusters in Cambridge, MA (85; 7.2%), San Francisco, CA (64; 5.5%), and New York, NY (39; 3.3%). There is also presence in Sacramento, CA (30), Washington, DC (25), West Sacramento, CA (23), Somerville, MA (17), and Seattle, WA (11). A sizable portion of employees are distributed across Other locations (428; 36.5%), reflecting a broad geographic footprint across many sites.
